<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02011451</url>
  </required_header>
  <id_info>
    <org_study_id>4818-A-1</org_study_id>
    <secondary_id>4816-A-1</secondary_id>
    <nct_id>NCT02011451</nct_id>
  </id_info>
  <brief_title>Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis</brief_title>
  <official_title>Safety and Neuroprotective Effects of Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Louisiana State University Health Sciences Center in New Orleans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Multiple Sclerosis Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Louisiana State University Health Sciences Center in New Orleans</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that 95% pure EGCG can protect brain cells in patients with Multiple&#xD;
      Sclerosis. To test this hypothesis we are going to compare the changes in n-Acetyl-Aspartate&#xD;
      (a chemical that reflects the number of neurons and their metabolism) over one six between&#xD;
      people with MS treated with EGCG at a dose of 400mg twice a day and people with MS treated&#xD;
      with a matching sugar pill.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a double blind placebo controlled trial of Theaphenon 95% (95% pure&#xD;
      Epigallo-catechin-galleate [EGCG]) as a treatment for MS.&#xD;
&#xD;
      The primary outcome will be the changes in N-Acety-Aspartate (NAA) levels over six months.&#xD;
      Secondary outcomes will be changes in brain atrophy over over six months. As an exploratory&#xD;
      outcome we will correlate changes in NAA levels with free Plasma levels of EGCG 8 hours after&#xD;
      the morning dose.&#xD;
&#xD;
      Exploratory outcomes include disability progression by Expanded Disability Status Scale&#xD;
      (EDSS), multiple sclerosis functional composite components and a cognitive test battery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    unable to enroll&#xD;
  </why_stopped>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of change in NAA levels adjusted for water content.</measure>
    <time_frame>6 months</time_frame>
    <description>The rate of change will be calculated using all the time points available (baseline,3 and 6 months) using a mixed model analysis with the Log NAA as the dependent variable and water content, %grey matter, %white matter, %cerebrospinal fluid (CSF) and % lesion volume as covariates. All the voxels available for each subject where estimates have a standard deviation(SD) &lt;30 will be used. A spatial anisotropic exponential covariance structure will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain Atrophy</measure>
    <time_frame>6 months</time_frame>
    <description>Difference between the two groups in brain atrophy as measured by SIENA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>95% Pure ECGC capsules 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>95% Pure ECGC capsules 200mg three times a day with food for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>95% Pure ECGC capsules 200mg</intervention_name>
    <description>Theaphenon 95% 95% Pure EGCG</description>
    <arm_group_label>95% Pure ECGC capsules 200mg</arm_group_label>
    <other_name>Theaphenon 95%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator:</intervention_name>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>&quot;Sugar pill&quot;</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of MS by McDonald criteria&#xD;
&#xD;
          -  Relapsing-remitting MS or secondary progressive MS&#xD;
&#xD;
          -  Stable therapy with Copaxone, Rebif, Betaseron or Avonex 30 mcg for at least six&#xD;
             months&#xD;
&#xD;
          -  EDSS Score less than or equal to 7.0&#xD;
&#xD;
          -  Ages 18-60.&#xD;
&#xD;
          -  Participants must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  Leukocytes ≥3,000/µL&#xD;
&#xD;
               -  Absolute neutrophil count ≥1,500/µL&#xD;
&#xD;
               -  Platelets ≥100,000/µL&#xD;
&#xD;
               -  Total bilirubin ≤local upper limit of normal&#xD;
&#xD;
               -  AST (SGOT) ≤local upper limit of normal&#xD;
&#xD;
               -  ALT (SGPT) ≤local upper limit of normal&#xD;
&#xD;
               -  Creatinine ≤local upper limit of normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MS relapse within the 30 days prior to enrollment&#xD;
&#xD;
          -  A primary progressive form of MS.&#xD;
&#xD;
          -  Previous treatment prior to study entry as follows: complete radiation ablation of the&#xD;
             bone marrow or anti-CD4 antibody treatment (Campath) at any time; mitoxantrone,&#xD;
             cyclophosphamide, Natalizumab or other immunomodulatory or immunosuppressant therapies&#xD;
             except the DMT's included in the inclusion criteria and methylprednisone for relapses&#xD;
             within prior nine months.&#xD;
&#xD;
          -  History of renal or liver disease.&#xD;
&#xD;
          -  Consumption of green tea or supplements containing green tea or tea extract within 30&#xD;
             days prior to enrollment.&#xD;
&#xD;
          -  Participants may not participate in any other clinical trial involving investigational&#xD;
             agents during the study, or within six months prior to enrolling in the study.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to Polyphenon E, tea, or any of the inactive ingredients present in the&#xD;
             active or placebo capsules, including gelatin.&#xD;
&#xD;
          -  History of allergic reactions to gadolinium or any other condition contraindicated for&#xD;
             MRI.&#xD;
&#xD;
          -  Uncontrolled, clinically-relevant active illness (aside from MS) including, but not&#xD;
             limited to, ongoing or active infection, symptomatic congestive heart failure,&#xD;
             unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations&#xD;
             that would limit compliance with study requirements.&#xD;
&#xD;
          -  Any condition which would make the subject, in the opinion of the investigator,&#xD;
             unsuitable for the study&#xD;
&#xD;
          -  Inability to complete the baseline MRI scan&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Any underlying predisposition to gastrointestinal bleeding (peptic ulcer disease,&#xD;
             gastritis, diverticulitis, colitis, hemorrhoids)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>LSU Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>December 10, 2013</study_first_submitted>
  <study_first_submitted_qc>December 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2013</study_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Louisiana State University Health Sciences Center in New Orleans</investigator_affiliation>
    <investigator_full_name>Jesus Lovera MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Green Tea</keyword>
  <keyword>ECGC</keyword>
  <keyword>Theaphenon</keyword>
  <keyword>Randomized placebo controlled trial</keyword>
  <keyword>NAA</keyword>
  <keyword>Spectroscopy</keyword>
  <keyword>Brain Atrophy</keyword>
  <keyword>SIENA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

